CBD Public Hearing Could Extend FDA's Hand Further For Help From Congress
Executive Summary
Among comments submitted to FDA's docket in advance of public hearing May 31, National Organization for the Reform of Marijuana Laws' suggestions perhaps point to path ahead for agency. "Regulations governing the production, sale, quality, and marketing of these products must take place far more expeditiously in order to protect consumer safety," the group says. FDA already appealed to Congress in its notice about docket and hearing, says attorney Coleen Klasmeier. "The notice is really a comment directed to Congress."
You may also be interested in...
Still No Appetite At US FDA For CBD In Food
Three years after similar warnings to make same impression, FDA warns five firms about using in food or beverage products CBD, the cannabinoid most commonly found in US, and delta-8 THC, a subject of ongoing discussion over whether it qualifies as hemp. One firm also warned about CBD in sunscreen.
‘Time Is Now’ For FDA Rule On Lawful CBD Use In Supplements, CRN Says In Citizen Petition
The trade group’s petition is second on a regulation for CBD’s use in non-drug products submitted to FDA and largely tracks with CHPA’s November 2019 petition. Comments continue to reach the FDA after in March it reopened its docket about establishing a CBD regulation, but with little data the agency says is needed for its decision.
US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements
As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.